Skip to main content

The Globe and Mail

Valeant Pharmaceuticals Intl Inc (VRX-T) Quote

Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 18.28
Day High 18.87
Open:18.30
Price movement based on the high, low and last over the given period.
Previous Close
Volume
Average Volume
Price/Earnings (TTM)
Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Description
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share ttm
Price/Earnings ttm
Annual Dividend & Yield
Ex-Div Date
Price/Book

Financials

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Latest Press Releases

TroyGould Advises Haitong International in its $190 Million Acquisition of Obagi Skincare Products Business
PR Newswire - Thu Nov 16, 12:00PM CST
PR Newswire - CMTX
Thu Nov 16, 12:00PM CST
TroyGould advised Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund") in its $190 million cash acquisition of the Obagi Medical Products business from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX). The Obagi line of premium skincare products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage and are primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals.
Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
PR Newswire - Wed Nov 15, 7:00AM CST
PR Newswire - CMTX
Wed Nov 15, 7:00AM CST
First Sponsored Contact Lens Recycling Program Collects More Than 7,000 lbs. of Waste
Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes
PR Newswire - Tue Nov 14, 3:10PM CST
PR Newswire - CMTX
Tue Nov 14, 3:10PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025. The Notes will be sold to investors at a price of 100.000% of the principal amount thereof plus accrued interest from October 17, 2017, representing a yield to worst of 5.498%. The offering is expected to close on or about November 21, 2017. Valeant intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term Loan Facilities due 2022 and to pay related fees and expenses.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 14.01 +34.19% increase
on 11/02/17
Period Open:16.04
Price movement based on the high, low and last over the given period.
19.95 -5.76% decrease
on 11/10/17
+2.76 (+17.21%) increase
since 10/17/17
3-Month 14.01 +34.19% increase
on 11/02/17
Period Open:18.18
Price movement based on the high, low and last over the given period.
19.95 -5.76% decrease
on 11/10/17
+0.62 (+3.41%) increase
since 08/17/17
52-Week 11.20 +67.86% increase
on 04/24/17
Period Open:24.30
Price movement based on the high, low and last over the given period.
25.22 -25.46% decrease
on 11/18/16
-5.50 (-22.63%) decrease
since 11/17/16

All market data is provided by Barchart Solutions (will open in new tab). Copyright © 2017.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).